Loading clinical trials...
Loading clinical trials...
Randomized, Double-blind, Safety and Efficacy Trial With Intravenous Zoledronic Acid for the Treatment of Paget's Disease of Bone Using Risedronate as a Comparator, Including an Extended Observational Period
Conditions
Interventions
Zoledronic Acid
Risedronate
+3 more
Locations
34
United States
Novartis Investigative Site
Santa Monica, California, United States
Novartis Investigative Site
Lakewood, Colorado, United States
Novartis Investigative Site
Boca Raton, Florida, United States
Novartis Investigative Site
Miami, Florida, United States
Novartis Investigative site
Maywood, Illinois, United States
Novartis investigative site
Worcester, Massachusetts, United States
Start Date
January 1, 2001
Primary Completion Date
March 1, 2004
Completion Date
April 1, 2011
Last Updated
May 15, 2012
NCT02802384
NCT00103740
NCT00747994
NCT00306046
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions